BioLineRx Statistics

Total Valuation

BioLineRx has a market cap or net worth of $19.90 million. The enterprise value is $6.35 million.

Market Cap	19.90M
Enterprise Value	6.35M

Important Dates

The next estimated earnings date is Thursday, August 14, 2025, before market open.

Earnings Date	Aug 14, 2025
Ex-Dividend Date	n/a

Share Statistics

BioLineRx has 2.23 billion shares outstanding. The number of shares has increased by 47.46% in one year.

Current Share Class	n/a
Shares Outstanding	2.23B
Shares Change (YoY)	+47.46%
Shares Change (QoQ)	+69.54%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	2.45B

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	0.89
Forward PS	n/a
PB Ratio	0.95
P/TBV Ratio	1.91
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	0.28
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 2.27, with a Debt / Equity ratio of 0.66.

Current Ratio	2.27
Quick Ratio	2.02
Debt / Equity	0.66
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-1.95

Financial Efficiency

Return on equity (ROE) is -20.03% and return on invested capital (ROIC) is -35.44%.

Return on Equity (ROE)	-20.03%
Return on Assets (ROA)	-21.98%
Return on Invested Capital (ROIC)	-35.44%
Return on Capital Employed (ROCE)	-56.72%
Revenue Per Employee	$797,857
Profits Per Employee	-$121,357
Employee Count	28
Asset Turnover	0.47
Inventory Turnover	2.53

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -80.26% in the last 52 weeks. The beta is 0.90, so BioLineRx's price volatility has been similar to the market average.

Beta (5Y)	0.90
52-Week Price Change	-80.26%
50-Day Moving Average	3.89
200-Day Moving Average	8.94
Relative Strength Index (RSI)	50.63
Average Volume (20 Days)	2,078,386

Short Selling Information

Short Interest	197,283
Short Previous Month	165,346
Short % of Shares Out	5.31%
Short % of Float	n/a
Short Ratio (days to cover)	0.11

Income Statement

In the last 12 months, BioLineRx had revenue of $22.34 million and -$3.40 million in losses. Loss per share was -$0.00.

Revenue	22.34M
Gross Profit	14.50M
Operating Income	-16.72M
Pretax Income	-49.15M
Net Income	-3.40M
EBITDA	-14.00M
EBIT	-16.72M
Loss Per Share	-$0.00

Full Income Statement

Balance Sheet

The company has $26.37 million in cash and $13.74 million in debt, giving a net cash position of $12.63 million or $0.01 per share.

Cash & Cash Equivalents	26.37M
Total Debt	13.74M
Net Cash	12.63M
Net Cash Per Share	$0.01
Equity (Book Value)	20.86M
Book Value Per Share	0.01
Working Capital	17.89M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$32.36 million and capital expenditures -$21,000, giving a free cash flow of -$32.38 million.

Operating Cash Flow	-32.36M
Capital Expenditures	-21,000
Free Cash Flow	-32.38M
FCF Per Share	-$0.01

Full Cash Flow Statement

Margins

Gross margin is 64.90%, with operating and profit margins of -74.85% and -15.21%.

Gross Margin	64.90%
Operating Margin	-74.85%
Pretax Margin	-15.21%
Profit Margin	-15.21%
EBITDA Margin	-62.67%
EBIT Margin	-74.85%
FCF Margin	n/a

Dividends & Yields

BioLineRx does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-47.46%
Shareholder Yield	-47.46%
Earnings Yield	-17.08%
FCF Yield	-162.71%

Analyst Forecast

The average price target for BioLineRx is $19.00, which is 328.89% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$19.00
Price Target Difference	328.89%
Analyst Consensus	Strong Buy
Analyst Count	2
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on January 30, 2025. It was a reverse split with a ratio of 0.025:1.

Last Split Date	Jan 30, 2025
Split Type	Reverse
Split Ratio	0.025:1

Scores

BioLineRx has an Altman Z-Score of -11.89 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-11.89
Piotroski F-Score	3